1. Home
  2. PRLB vs TSHA Comparison

PRLB vs TSHA Comparison

Compare PRLB & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Proto Labs Inc.

PRLB

Proto Labs Inc.

HOLD

Current Price

$79.64

Market Cap

1.7B

Sector

Industrials

ML Signal

HOLD

Logo Taysha Gene Therapies Inc.

TSHA

Taysha Gene Therapies Inc.

HOLD

Current Price

$6.14

Market Cap

1.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PRLB
TSHA
Founded
1999
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Metal Fabrications
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
1.8B
IPO Year
2011
2020

Fundamental Metrics

Financial Performance
Metric
PRLB
TSHA
Price
$79.64
$6.14
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
8
Target Price
$53.00
$11.63
AVG Volume (30 Days)
205.6K
2.8M
Earning Date
05-01-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
33.33
5.56
EPS
0.33
N/A
Revenue
N/A
$9,773,000.00
Revenue This Year
$8.56
N/A
Revenue Next Year
$6.89
$1,152.42
P/E Ratio
$246.12
N/A
Revenue Growth
N/A
17.28
52 Week Low
$38.48
$2.25
52 Week High
$83.15
$7.30

Technical Indicators

Market Signals
Indicator
PRLB
TSHA
Relative Strength Index (RSI) 59.54 52.09
Support Level $52.62 $6.11
Resistance Level $83.15 $6.76
Average True Range (ATR) 2.98 0.42
MACD -0.09 0.07
Stochastic Oscillator 65.02 49.86

Price Performance

Historical Comparison
PRLB
TSHA

About PRLB Proto Labs Inc.

Proto Labs Inc is an on-demand manufacturer of custom parts for prototyping and short-run production. The company offers developers and engineers quick-turn production services to reduce the time to market. The Lab uses injection molding, computer numerical control machining, and 3-D printing, and sheet metal to manufacture custom parts for its clients. The company services clients' needs for prototype solutions, parts for testing procedures, bridge production capabilities during disruptions in manufacturing processes, limited-quantity requests, and end-of-life production support. Geographically, a majority of the company's revenue is derived from the United States and the rest from Europe.

About TSHA Taysha Gene Therapies Inc.

Taysha Gene Therapies Inc is a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS. The company's clinical program TSHA-102 is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. The Company views its operations and manages its business as a single operating segment, the gene therapy segment, which is the business of developing AAV-based gene therapies for the treatment of rare monogenic diseases of the central nervous system.

Share on Social Networks: